dacomitinib
Selected indexed studies
- Dacomitinib. (, 2006) [PMID:30372001]
- Dacomitinib. (, 2012) [PMID:31643328]
- Dacomitinib: First Global Approval. (Drugs, 2018) [PMID:30506139]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dacomitinib. (2006) pubmed
- Dacomitinib. (2012) pubmed
- Dacomitinib: First Global Approval. (2018) pubmed
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. (2017) pubmed
- Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. (2019) pubmed
- Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. (2019) pubmed
- Dacomitinib: an investigational drug for the treatment of glioblastoma. (2018) pubmed
- Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. (2019) pubmed
- Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. (2019) pubmed
- PMID:40934352 (2019) pubmed